RxDoctor Payments Data

Joshua Stern, MD

Internal Medicine · New Hyde Park, NYNPI 1922087188

Payments from drug & device makers

$125,872in general payments, 2019–2025

Across 575 payments — averaging $218.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$69K
  • Kestra Medical Technology Services, Inc.$31K
  • Biotronik Inc.$20K
  • Biosense Webster, Inc.$2K
  • Medtronic$1K
  • Impulse Dynamics (USA) Inc.$1K
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$99,49279%
  • Speaking & faculty fees$5,4504%
  • Travel & lodging$7941%
  • Food & beverage$19,53916%
  • Education$5970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,872 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,912,999
Medicare patients
2,102
Services billed
11,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban545$632,755
XareltoRivaroxaban153$180,969
MultaqDronedarone Hcl91$121,787
Metoprolol Succinate420$7,939
Mexiletine Hcl34$3,762
Amiodarone Hcl125$2,774
SotalolSotalol Hcl56$1,338
Pantoprazole Sodium95$708
Diltiazem 24hr Er (Xr)Diltiazem Hcl12$427
Carvedilol42$376
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$376
ClopidogrelClopidogrel Bisulfate23$334
Omeprazole14$142
Metoprolol Tartrate13$109
Atenolol12$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$632,755545 claims
Johnson & JohnsonXarelto$240$180,969153 claims
Sanofi-aventis U.S. LLCMultaq$21$121,78791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →